microRNAs: Small molecules with a large impact on colorectal cancer

Diagnosis; RNA; Cancer development; Early diagnosis; Expression templates; Molecular mechanism; RNA molecules; Signalling pathways; Small molecules; Transcription profiles; Treatment outcomes; Diseases

Abstract :

[en] Colorectal cancer (CRC) accounts for one of the main cancer-related mortality and morbidity worldwide. The molecular mechanisms of CRC development have been broadly investigated and, over the last decade, it has become evident that aberrant transcription of microRNAs (miRNAs), a class of small, noncoding RNA molecules, has a significant role in the inception and promotion of CRC. In the involved tissues of CRC, the transcription profile of miRNAs is modulated, and their expression templates are related with prognosis, diagnosis, and treatment outcomes. Here, in the current review, we attempted to discuss the latest information regarding the aberrantly expressed miRNAs in CRC and the advantages of utilizing miRNAs as biomarkers for early diagnosis and prognosis of CRC as well as potential therapeutic application. The effect of miRNAs involved in various signaling pathways, primarily p53, EGFR, Wnt, and TGF-β pathways, was clarified. © 2021 International Union of Biochemistry and Molecular Biology, Inc.

Disciplines :

Immunology & infectious disease

Author, co-author :

Moazzendizaji, S.; Department of Immunology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

Sevbitov, A.; Head of Department of Propaedeutics of Dental Diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation

Ezzatifar, F.; Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran, Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

Jalili, H. R.; Department of Immunology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

Aalii, M.; Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

Hemmatzadeh, M.; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

Aslani, S.; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Gholizadeh Navashenaq, J.; Noncommunicable Diseases Research Center, Bam University of Medical Sciences, Bam, Iran

Safari, Roghaiyeh ; Université de Liège - ULg

Hosseinzadeh, R.; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Rahmany, M. R.; Department of Immunology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

Mohammadi, H.; Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran, Department of Immunology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran

Language :

English

Title :

microRNAs: Small molecules with a large impact on colorectal cancer

Publication date :

2021

Journal title :

Biotechnology and Applied Biochemistry

ISSN :

0885-4513

eISSN :

1470-8744

Publisher :

Wiley-Blackwell, United States

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 04 January 2022

Statistics

Number of views

47 (4 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Malki A, ElRuz RA, Gupta I, Allouch A, Vranic S, Al Moustafa A-E. Molecular mechanisms of colon cancer progression and metastasis: recent insights and advancements. Int. J. Mol. Sci. 2021;22:130.
Sabry D, El-Deek SE, Maher M, El-Baz MA, El-Bader HM, Amer E, et al. Role of miRNA-210, miRNA-21 and miRNA-126 as diagnostic biomarkers in colorectal carcinoma: impact of HIF-1Î±-VEGF signaling pathway. Mol. Cell. Biochem. 2019;454:177–189.
Sieuwerts AM, Lalmahomed ZS, Smid M, Wilting SM, Bril SI, Xiang S, et al. Confirmation of a metastasis-specific microRNA signature in primary colon cancer. Sci. Rep. 2018;8:1–11.
Willett CG, Chang DT, Czito BG, Meyer J, Wo J. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012. Int. J. Radiat. Oncol. Biol. Phys. 2013;86(5).
Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 2015;21:1350.
Magrin L, Fanale D, Brando C, Fiorino A, Corsini LR, Sciacchitano R, et al. POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes. Oncogene. 2021 https://doi.org/10.1038/s41388-021-01984-2.
Ahmed FE. miRNA as markers for the diagnostic screening of colon cancer. Expert Rev. Anticancer Ther. 2014;14:463–485.
Hemmatzadeh M, Mohammadi H, Karimi M, Musavishenas MH, Baradaran B. Differential role of microRNAs in the pathogenesis and treatment of Esophageal cancer. Biomed. Pharmacother. 2016;82:509–519.
Hemmatzadeh M, Mohammadi H, Jadidi-Niaragh F, Asghari F, Yousefi M The role of oncomirs in the pathogenesis and treatment of breast cancer. Biomed. Pharmacother. 2016;78:129–139.
Hemmatzadeh M, Shomali N, Yousefzadeh Y, Mohammadi H, Ghasemzadeh A, Yousefi M. MicroRNAs: Small molecules with a large impact on pre-eclampsia. J. Cell. Physiol. 2020;235:3235–3248.
Mohammadi H, Hemmatzadeh M, Babaie F, Gowhari Shabgah A, Azizi G, Hosseini F, et al. MicroRNA implications in the etiopathogenesis of ankylosing spondylitis. J Cell Physiol. 2018;233:5564–5573.
Aghdam SG, Ebrazeh M, Hemmatzadeh M, Seyfizadeh N, Shabgah AG, Azizi G, et al. The role of microRNAs in prostate cancer migration, invasion, and metastasis. J Cell Physiol. 2019;234:9927–9942.
Saidi N, Ghalavand M, Hashemzadeh MS, Dorostkar R, Mohammadi H, Mahdian-Shakib A. Dynamic changes of epigenetic signatures during chondrogenic and adipogenic differentiation of mesenchymal stem cells. Biomed Pharmacother. 2017;89:719–731.
Gungormez C, Aktas HG, Dilsiz N, Borazan E. Novel miRNAs as potential biomarkers in stage II colon cancer: microarray analysis. Mol. Biol. Rep. 2019;46:4175–4183.
Peng J, Xie Z, Cheng L, Zhang Y, Chen J, Yu H, et al. Paired design study by real-time PCR: miR-378* and miR-145 are potent early diagnostic biomarkers of human colorectal cancer. BMC Cancer. 2015;15:1–7.
Danbaran GR, Aslani S, Sharafkandi N, Hemmatzadeh M, Hosseinzadeh R, Azizi G, et al. How microRNAs affect the PD-L1 and its synthetic pathway in cancer. Int Immunopharmacol. 2020;84:106594.
Ebrahimi N, Aslani S, Babaie F, Hemmatzadeh M, Pourmoghadam Z, Azizi G, et al. MicroRNAs implications in the onset, diagnosis, and prognosis of osteosarcoma. Curr Mol Med 2020. https://doi.org/10.2174/1566524020999201203212824.
Hofsli E, Sjursen W, Prestvik W, Johansen J, Rye M, Tranø G, et al. Identification of serum microRNA profiles in colon cancer. Br. J. Cancer. 2013;108:1712–1719.
Schetter AJ, Nguyen GH, Bowman ED, Mathé EA, Yuen ST, Hawkes JE, et al. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin. Cancer Res. 2009;15:5878–5887.
Sazanov AA, Kiselyova E, Zakharenko A, Romanov MN, Zaraysky M. Plasma and saliva miR-21 expression in colorectal cancer patients. J. Appl. Genet. 2017;58:231–237.
Wu Y, Song Y, Xiong Y, Wang X, Xu K, Han B, et al. MicroRNA-21 (Mir-21) promotes cell growth and invasion by repressing tumor suppressor PTEN in colorectal cancer. Cell. Physiol. Biochem. 2017;43:945–958.
Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299:425–436.
Wang W, Qu A, Liu W, Liu Y, Zheng G, Du L, et al. Circulating miR-210 as a diagnostic and prognostic biomarker for colorectal cancer. Eur. J. Cancer Care (Engl). 2017;26:e12448.
Di Z, Di M, Fu W, Tang Q, Liu Y, Lei P, et al. Integrated analysis identifies a nine-microRNA signature biomarker for diagnosis and prognosis in colorectal cancer. Frontiers in Genetics 2020;11:192.
Li G, Wang Q, Li Z, Shen Y. Serum miR-21 and miR-210 as promising non-invasive biomarkers for the diagnosis and prognosis of colorectal cancer. Revista Espanola de Enfermedades Digestivas: Organo Oficial de la Sociedad Espanola de Patologia Digestiva. 2020.
Yang Y, Gu J, Li X, Xue C, Ba L, Gao Y, et al. HIF-1α promotes the migration and invasion of cancer-associated fibroblasts by miR-210. Aging and Disease. 2021:0.
Nassar F, Msheik Z, Itani M, Helou R, Hadla R, Kreidieh F, et al. Circulating miRNA as Biomarkers for Colorectal Cancer Diagnosis and Liver Metastasis. Diagnostics 2021, 11, 341, s Note: MDPI stays neutral with regard to jurisdictional. claims in published…. 2021
Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature. 2012;481:190–194.
Almeida ALNRD, Bernardes MVAA, Feitosa MR, Peria FM, Tirapelli DPDC, Rocha JJRD, et al. Serological under expression of microRNA-21, microRNA-34a and microRNA-126 in colorectal cancer. Acta Cirurgica Brasileira. 2016;31:13–18.
Wei L, Chen Z, Cheng N, Li X, Chen J, Wu D, et al. MicroRNA-126 inhibit viability of colorectal cancer cell by repressing mTOR induced apoptosis and autophagy. OncoTargets and Therapy. 2020;13:2459.
Huang W, Lin J, Zhang H. miR-126: a novel regulator in colon cancer. Biomedical Reports. 2016;4:131–134.
Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J. Gastroenterol. Hepatol. 2010;25:1674–1680.
Schetter AJ, Okayama H, Harris CC. The role of microRNAs in colorectal cancer. Cancer J. 2012;18:244.
Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, et al. Prognostic values of microRNAs in colorectal cancer. Biomarker Insights. 2006;1:117727190600100009.
Díaz R, Silva J, García JM, Lorenzo Y, García V, Peña C, et al. Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer. 2008;47:794–802.
Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjøt L, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 2008;68:6416–6424.
Nishida N, Yokobori T, Mimori K, Sudo T, Tanaka F, Shibata K, et al. MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int. J. Oncol. 2011;38:1437–1443.
Drebber U, Lay M, Wedemeyer I, VALLböHMER D, Bollschweiler E, Brabender J, et al. Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Int. J. Oncol. 2011;39:409–415.
Akcakaya P, Ekelund S, Kolosenko I, Caramuta S, Özata DM, Xie H, et al. miR-185 and miR-133b deregulation is associated with overall survival and metastasis in colorectal cancer. Int. J. Oncol. 2011;39:311–318.
Karaayvaz M, Pal T, Song B, Zhang C, Georgakopoulos P, Mehmood S, et al. Prognostic significance of miR-215 in colon cancer. Clin. Colorectal Cancer. 2011;10:340–347.
Yu G, Tang JQ, Tian ML, Li H, Wang X, Wu T, et al. Prognostic values of the miR-17-92 cluster and its paralogs in colon cancer. J. Surg. Oncol. 2012;106:232–237.
Maierthaler M, Benner A, Hoffmeister M, Surowy H, Jansen L, Knebel P, et al. Plasma miR-122 and miR-200 family are prognostic markers in colorectal cancer. Int. J. Cancer. 2017;140:176–187.
Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology. 2010;79:313–320.
Nielsen BS, Jørgensen S, Fog JU, Søkilde R, Christensen IJ, Hansen U, et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin. Exp. Metastasis. 2011;28:27–38.
Li J, Liu Y, Wang C, Deng T, Liang H, Wang Y, et al. Serum miRNA expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma. Sci. Rep. 2015;5:1–13.
Liu G-H, Zhou Z-G, Chen R, Wang M-J, Li Y, Sun X-F. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. Tumor biology. 2013;34:2175–2181.
Imaoka H, Toiyama Y, Fujikawa H, Hiro J, Saigusa S, Tanaka K, et al. Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer. Ann. Oncol. 2016;27:1879–1886.
Yuan D, Li K, Zhu K, Yan R, Dang C. Plasma miR-183 predicts recurrence and prognosis in patients with colorectal cancer. Cancer Biol. Ther. 2015;16:268–275.
Hur K, Toiyama Y, Schetter AJ, Okugawa Y, Harris CC, Boland CR, et al. Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. J. Natl. Cancer Inst. 2015;107:dju492.
Liu M, Zhi Q, Wang W, Zhang Q, Fang T, Ma Q. Up-regulation of miR-592 correlates with tumor progression and poor prognosis in patients with colorectal cancer. Biomed. Pharmacother. 2015;69:214–220.
Xu C, Gu L. The diagnostic effect of serum miR-196b as biomarker in colorectal cancer. Biomedical reports. 2017;6:39–45.
Lv Z-C, Fan Y-S, Chen H-B, Zhao D-W. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer. Tumor Biology. 2015;36:1619–1625.
Sun Y, Yang B, Lin M, Yu H, Chen H, Zhang Z. Identification of serum miR-30a-5p as a diagnostic and prognostic biomarker in colorectal cancer. Cancer Biomarkers. 2019;24:299–305.
Basati G, Razavi AE, Pakzad I, Malayeri FA. Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer. Tumor biology. 2016;37:1781–1788.
Kou CH, Zhou T, Han XL, Zhuang HJ, Qian HX. Downregulation of mir-23b in plasma is associated with poor prognosis in patients with colorectal cancer. Oncol. Lett. 2016;12:4838–4844.
Liu W, Qian K, Wei X, Deng H, Zhao B, Chen Q, et al. miR-27a promotes proliferation, migration, and invasion of colorectal cancer by targeting FAM172A and acts as a diagnostic and prognostic biomarker. Oncol. Rep. 2017;37:3554–3564.
Liu X, Pan B, Sun L, Chen X, Zeng K, Hu X, et al. Circulating exosomal miR-27a and miR-130a act as novel diagnostic and prognostic biomarkers of colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 2018;27:746–754.
Matsumura T, Sugimachi K, Iinuma H, Takahashi Y, Kurashige J, Sawada G, et al. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br. J. Cancer. 2015;113:275–281.
Yan S, Han B, Gao S, Wang X, Wang Z, Wang F, et al. Exosome-encapsulated microRNAs as circulating biomarkers for colorectal cancer. Oncotarget. 2017;8:60149.
Hu H-Y, Yu C-H, Zhang H-H, Zhang S-Z, Yu W-Y, Yang Y, et al. Exosomal miR-1229 derived from colorectal cancer cells promotes angiogenesis by targeting HIPK2. Int. J. Biol. Macromol. 2019;132:470–477.
Liu C, Eng C, Shen J, Lu Y, Takata Y, Mehdizadeh A, et al. Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer. Oncotarget. 2016;7:76250.
Fu F, Jiang W, Zhou L, Chen Z. Circulating exosomal miR-17-5p and miR-92a-3p predict pathologic stage and grade of colorectal cancer. Translational oncology. 2018;11:221–232.
Fanale D, Barraco N, Listì A, Bazan V, Russo A. Non-coding RNAs functioning in colorectal cancer stem cells. Non-coding RNAs in Colorectal Cancer. 2016;93–108.
Song B, Wang Y, Xi Y, Kudo K, Bruheim S, et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene. 2009;28:4065–4074.
Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, et al. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol. Cancer. 2010;9:1–10.
Jones MF, Hara T, Francis P, Li XL, Bilke S, Zhu Y, et al. The CDX1.-microRNA-215 axis regulates colorectal cancer stem cell differentiation. Proceedings of the National Academy of Sciences USA. 2015;112:E1550-E1558.
Wang LQ, Yu P, Li B, Guo YH, Liang ZR, Zheng LL, et al. miR-372 and miR-373 enhance the stemness of colorectal cancer cells by repressing differentiation signaling pathways. Molecular oncology. 2018;12:1949–1964.
Monzo M, Navarro A, Bandres E, Artells R, Moreno I, Gel B, et al. Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell Res. 2008;18:823–833.
Zhai H, Fesler A, Ba Y, Wu S, Ju J. Inhibition of colorectal cancer stem cell survival and invasive potential by hsa-miR-140-5p mediated suppression of Smad2 and autophagy. Oncotarget. 2015;6:19735.
Zhai H, Song B, Xu X, Zhu W, Ju J. Inhibition of autophagy and tumor growth in colon cancer by miR-502. Oncogene. 2013;32:1570–1579.
Fesler A, Zhai H, Ju J. miR-129 as a novel therapeutic target and biomarker in gastrointestinal cancer. OncoTargets and therapy. 2014;7:1481.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767.
Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138:2059–2072.
Mohammadi A, Mansoori B, Baradaran B. The role of microRNAs in colorectal cancer. Biomed. Pharmacother. 2016;84:705–713.
Hofacker IL. How microRNAs choose their targets. Nat. Genet. 2007;39:1191–1192.
Wang J, Du Y, Liu X, Cho WC, Yang Y. MicroRNAs as regulator of signaling networks in metastatic colon cancer. Biomed. Res. Int. 2015;2015.
Clevers H, Loh KM, Nusse R. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science. 2014;346.
Yu Y, Kanwar SS, Patel BB, Oh P-S, Nautiyal J, Sarkar FH, et al. MicroRNA-21 induces stemness by downregulating transforming growth factor beta receptor 2 (TGFβR2) in colon cancer cells. Carcinogenesis. 2012;33:68–76.
Zhang H, Hao Y, Yang J, Zhou Y, Li J, Yin S, et al. Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis. Nat. Commun. 2011;2:1–11.
Zhang Z, Kim K, Li X, Moreno M, Sharp T, Goodheart MJ, et al. MicroRNA-26b represses colon cancer cell proliferation by inhibiting lymphoid enhancer factor 1 expression. Mol. Cancer Ther. 2014;13:1942–1951.
Zhang F, Meng F, Li H, Dong Y, Yang W, Han A. Suppression of retinoid X receptor alpha and aberrant β-catenin expression significantly associates with progression of colorectal carcinoma. Eur. J. Cancer. 2011;47:2060–2067.
Saberinia A, Alinezhad A, Jafari F, Soltany S, Sigari RA. Oncogenic miRNAs and target therapies in colorectal cancer. Clin. Chim. Acta. 2020.
Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol. Cancer. 2009;8:1–13.
Liang C, Fu Y, Liu Z, Xing B, Jin Y, Huang J. The effect of miR-224 down-regulation on SW80 cell proliferation and apoptosis and weakening of ADM drug resistance. Eur Rev Med Pharmacol Sci. 2017;21:5008–5016.
Fasihi A, Soltani BM, Atashi A, Nasiri S. Introduction of hsa-miR-103a and hsa-miR-1827 and hsa-miR-137 as new regulators of Wnt signaling pathway and their relation to colorectal carcinoma. J. Cell. Biochem. 2018;119:5104–5117.
Tang Q, Zou Z, Zou C, Zhang Q, Huang R, Guan X, et al. MicroRNA-93 suppress colorectal cancer development via Wnt/β-catenin pathway downregulating. Tumor Biology. 2015;36:1701–1710.
Ji D, Chen Z, Li M, Zhan T, Yao Y, Zhang Z, et al. MicroRNA-181a promotes tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1. Mol. Cancer. 2014;13:1–18.
Yee DS, Tang Y, Li X, Liu Z, Guo Y, Ghaffar S, et al. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. Mol. Cancer. 2010;9:1–14.
Li Y, Lauriola M, Kim D, Francesconi M, D'Uva G, Shibata D, et al. Adenomatous polyposis coli (APC) regulates miR17-92 cluster through β-catenin pathway in colorectal cancer. Oncogene. 2016;35:4558–4568.
Wan YC, Li T, Han YD, Zhang HY, Lin H, Zhang B. MicroRNA-155 enhances the activation of Wnt/β-catenin signaling in colorectal carcinoma by suppressing HMG-box transcription factor 1. Molecular medicine reports. 2016;13:2221–2228.
Wu WK, Law PT, Lee CW, Cho CH, Fan D, Wu K, et al. MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis. 2011;32:247–253.
Suto T, Yokobori T, Yajima R, Morita H, Fujii T, Yamaguchi S, et al. MicroRNA-7 expression in colorectal cancer is associated with poor prognosis and regulates cetuximab sensitivity via EGFR regulation. Carcinogenesis. 2015;36:338–345.
Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009;28:1385–1392.
Saridaki Z, Weidhaas JB, Lenz H-J, Laurent-Puig P, Jacobs B, De Schutter J, et al. A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Clin. Cancer Res. 2014;20:4499–4510.
Yau T, Wu C, Dong Y, Tang C, Ng S, Chan F, et al. microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma. Br. J. Cancer. 2014;111:1765–1771.
Ibrahim H, Lim YC. KRAS-associated microRNAs in colorectal cancer. Oncology Reviews. 2020;14.
Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA. Portrait of the PI3K/AKT pathway in colorectal cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2015;1855:104–121.
Guo C, Sah JF, Beard L, Willson JK, Markowitz SD, Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer. 2008;47:939–946.
Humphreys KJ, Cobiac L, Le Leu RK, Van der Hoek MB, Michael MZ. Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Mol. Carcinog. 2013;52:459–474.
Li J, Zhang Y, Zhao J, Kong F, Chen Y. Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol. Cell. Biochem. 2011;357:31–38.
Carvalho TID, Novais PC, Lizarte Neto FS, Sicchieri RD, Rosa MST, Carvalho CAMD, et al. Analysis of gene expression EGFR and KRAS, microRNA-21 and microRNA-203 in patients with colon and rectal cancer and correlation with clinical outcome and prognostic factors. Acta cirurgica brasileira. 2017;32:243–250.
Slattery ML, Mullany LE, Wolff RK, Sakoda LC, Samowitz WS, Herrick JS. The p53-signaling pathway and colorectal cancer: Interactions between downstream p53 target genes and miRNAs. Genomics. 2019;111:762–771.
Mandinova A, Lee SW. The p53 pathway as a target in cancer therapeutics: obstacles and promise. Sci. Transl. Med. 2011;3:64rv61-64rv61.
Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer. 2014;14:359–370.
Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proceedings of the National Academy of Sciences USA. 2008;105:13421–13426.
Lu G, Sun Y, An S, Xin S, Ren X, Zhang D, et al. MicroRNA-34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer. Exp. Mol. Pathol. 2015;99:173–179.
Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007;6:1586–1593.
Slattery ML, Herrick JS, Pellatt DF, Mullany LE, Stevens JR, Wolff E, et al. Site-specific associations between miRNA expression and survival in colorectal cancer cases. Oncotarget. 2016;7:60193.
Agarwal S, Behring M, Kim HG, Chandrashekar DS, Chakravarthi BV, Gupta N, et al. TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status. Molecular oncology. 2020;14:3007–3029.
Zhang C, Liu J, Wang X, Wu R, Lin M, Laddha SV, et al. MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling. Oncotarget. 2014;5:9106.
Dong Y, Zhao J, Wu C-W, Zhang L, Liu X, Kang W, et al. Tumor Suppressor Functions of miR-133a in Colorectal Cancer. Mol. Cancer Res. 2013.
Butz H, Rácz K, Hunyady L, Patócs A. Crosstalk between TGF-β signaling and the microRNA machinery. Trends Pharmacol. Sci. 2012;33:382–393.
Li B, Huang M, Liu M, Wen S, Sun F. MicroRNA-329 serves a tumor suppressive role in colorectal cancer by directly targeting transforming growth factor beta-1. Molecular medicine reports. 2017;16:3825–3832.
Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat. Genet. 2006;38:1060–1065.
Bao Y, Chen Z, Guo Y, Feng Y, Li Z, Han W, et al. Tumor suppressor microRNA-27a in colorectal carcinogenesis and progression by targeting SGPP1 and Smad2. PLoS One. 2014;9: e105991.
Liu L, Nie J, Chen L, Dong G, Du X, Wu X, et al. The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression. PLoS One. 2013;8:e55532.
Zhao W, Zou J, Wang B, Fan P, Mao J, Li J, et al. microRNA-140 suppresses the migration and invasion of colorectal cancer cells through targeting Smad3. Zhonghua Zhong Liu Za Zhi. 2014;36:739–745.
Li Q, Zou C, Zou C, Han Z, Xiao H, Wei H, et al. MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. Cancer Lett. 2013;335:168–174.
Zhao S, Sun H, Jiang W, Mi Y, Zhang D, Wen Y, et al. miR-4775 promotes colorectal cancer invasion and metastasis via the Smad7/TGFβ-mediated epithelial to mesenchymal transition. Mol. Cancer. 2017;16:1–14.
Li J, Liang H, Bai M, Ning T, Wang C, Fan Q, et al. miR-135b Promotes Cancer Progression by Targeting Transforming Growth Factor Beta Receptor II (TGFBR2) in Colorectal Cancer. PLoS One. 2015;10:e0130194.
Zhang W, Zhang T, Jin R, Zhao H, Hu J, Feng B, et al. MicroRNA-301a promotes migration and invasion by targeting TGFBR2 in human colorectal cancer. J. Exp. Clin. Cancer Res. 2014;33:1–13.
Yi R, Li Y, Wang F-L, Miao G, Qi R-M, Zhao Y-Y. MicroRNAs as diagnostic and prognostic biomarkers in colorectal cancer. World. J. Gastrointest. Oncol. 2016;8:330.
Mencia N, Selga E, Noé V, Ciudad CJ. Underexpression of miR-224 in methotrexate resistant human colon cancer cells. Biochem. Pharmacol. 2011;82:1572–1582.
Nedaeinia R, Sharifi M, Avan A, Kazemi M, Rafiee L, Ghayour-Mobarhan M, et al. Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach. Cancer Gene Ther. 2016;23:246–253.
Chai H, Liu M, Tian R, Li X, Tang H. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines. Acta Biochim Biophys Sin. 2011;43:217–225.
Huang Z, Huang S, Wang Q, Liang L, Ni S, Wang L, et al. MicroRNA-95 promotes cell proliferation and targets sorting Nexin 1 in human colorectal carcinoma. Cancer Res. 2011;71:2582–2589.
Tsang WP, Ng EK, Ng SS, Jin H, Yu J, Sung JJ, et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis. 2010;31:350–358.
Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, et al. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res. 2016;76:3690–3701.
Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, et al. Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics-Proteomics. 2006;3:317–324.
Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, et al. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann. Oncol. 2011;22:104–109.
Xing J, Wan S, Zhou F, Qu F, Li B, Myers RE, et al. Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 2012;21:217–227.
Li X, Zhao H, Zhou X, Song L. Inhibition of lactate dehydrogenase A by microRNA-34a resensitizes colon cancer cells to 5-fluorouracil. Molecular medicine reports. 2015;11:577–582.
Yu X, Li Z, Yu J, Chan MT, Wu WK. MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer. Cell Prolif. 2015;48:503–510.
Zhang Y, Geng L, Talmon G, Wang J. MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. J. Biol. Chem. 2015;290:6215–6225.
Zhang L, Pickard K, Jenei V, Bullock MD, Bruce A, Mitter R, et al. miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res. 2013;73:6435–6447.
Guo S, Jiang C, Wang G, Li Y, Wang C, Guo X, et al. MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer. Oncogene. 2013;32:1910–1920.
Tan S, Shi H, Ba M, Lin S, Tang H, Zeng X, et al. miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy. Int. J. Mol. Med. 2016;37:1030–1038.
Xu J, Zhang G, Luo X, Wang D, Zhou W, Zhang Y, et al. Co-delivery of 5-fluorouracil and miRNA-34a mimics by host-guest self-assembly nanocarriers for efficacious targeted therapy in colorectal cancer patient-derived tumor xenografts. Theranostics. 2021;11:2475.
Poel D, Boyd LN, Beekhof R, Schelfhorst T, Pham TV, Piersma SR, et al. Proteomic analysis of miR-195 and miR-497 replacement reveals potential candidates that increase sensitivity to oxaliplatin in MSI/P53wt colorectal cancer cells. Cells 2019;8:1111.
Arghiani N, Matin MM. miR-21: A Key Small Molecule with Great Effects in Combination Cancer Therapy. Nucleic Acid Ther. 2021.
Mekenkamp LJ, Tol J, Dijkstra JR, de Krijger I, Vink-Börger ME, van Vliet S, et al. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer. 2012;12:1–11.
García-Aranda M, Redondo M. Targeting receptor kinases in colorectal cancer. Cancers. 2019;11:433.
Moradi Marjaneh R, Khazaei M, Ferns GA, Avan A, Aghaee-Bakhtiari SH. MicroRNAs as potential therapeutic targets to predict responses to oxaliplatin in colorectal cancer: From basic evidence to therapeutic implication. IUBMB Life. 2019;71:1428–1441.
Wu Y, Cong L, Chen W, Wang X, Qiu F. lncRNA LINC00963 downregulation regulates colorectal cancer tumorigenesis and progression via the miR‑10b/FGF13 axis. Molecular medicine reports. 2021;23:1-1.
To KK, Leung W, Ng SS. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer. Exp. Cell Res. 2015;338:222–231.
Jung E, Choi J, Kim J-S, Han T-S. MicroRNA-based therapeutics for drug-resistant Colorectal Cancer. Pharmaceuticals. 2021;14:136.
Perez-Carbonell L, Sinicrope FA, Alberts SR, Oberg AL, Balaguer F, Castells A, et al. MiR-320e is a novel prognostic biomarker in colorectal cancer. Br. J. Cancer. 2015;113:83–90.
Wang X, Jiang G, Ren W, Wang B, Yang C, Li M. LncRNA NEAT1 Regulates 5-Fu Sensitivity, Apoptosis and Invasion in Colorectal Cancer Through the MiR-150-5p/CPSF4 Axis. OncoTargets and therapy. 2020;13:6373.
Xiao Z, Chen S, Feng S, Li Y, Zou J, Ling H, et al. Function and mechanisms of microRNA‑20a in colorectal cancer. Experimental and therapeutic medicine. 2020;19:1605–1616.
Du Q, Du N, Zhu C, Shang Q, Mao H, Li X, et al. miR-203 regulates proliferation and apoptosis of Colorectal Cancer cells through targeting DJ-1. Journal of Biomaterials and Tissue Engineering. 2020;10:365–370.
Kumar S, Agnihotri N. Piperlongumine, a piper alkaloid targets Ras/PI3K/Akt/mTOR signaling axis to inhibit tumor cell growth and proliferation in DMH/DSS induced experimental colon cancer. Biomed. Pharmacother. 2019;109:1462–1477.
Hu J, Cai G, Xu Y, Cai S. The Plasma microRNA miR-1914* and-1915 suppresses chemoresistant in Colorectal Cancer patients by down-regulating NFIX. Curr. Mol. Med. 2016;16:70–82.
Kjersem J, Ikdahl T, Lingjaerde O, Guren T, Tveit K, Kure E. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. Molecular oncology. 2014;8:59–67.
Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, Nekvindova J, et al. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat. Oncol. 2012;7:1–7.
Shi L, Xi J, Xu X, Peng B, Zhang B. MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells. Biomed. Pharmacother. 2019;109:902–909.
Xu F, Ye ML, Zhang YP, Li WJ, Li MT, Wang HZ, et al. MicroRNA-375-3p enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer. Cancer Sci. 2020;111:1528.
Liu N, Li J, Zhao Z, Han J, Jiang T, Chen Y, et al. MicroRNA-302a enhances 5-fluorouracil-induced cell death in human colon cancer cells. Oncol. Rep. 2017;37:631–639.
Chang Y-L, Liu S-T, Wang Y-W, Lin W-S, Huang S-M. Amiodarone promotes cancer cell death through elevated truncated SRSF3 and downregulation of miR-224. Oncotarget. 2018;9:13390.